VidPrevtyn Beta 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
II/0007/G 
This was an application for a group of variations. 
15/02/2024 
SmPC 
The update of Section 4.8 of the SmPC was based on the 
A grouped application consisting of: 
Type II (C.I.4): Update of section 4.8 of the SmPC in 
order to include additional safety data based on 
safety update reports from studies VAT00008 
analysis of safety data that have been accrued with the 
monovalent B.1.351 vaccine booster formulation from the 
MAH’s safety database with over 3000 participants with at 
least 6 weeks of follow-up. 
The ATC Code is also being updated as per WHO’s latest 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
booster extension and VAT00002 Cohort 2, in order 
recommendations.  
to fulfill REC 20. 
Type IA (A.6): To change the ATC Code of the 
COVID-19 protein subunit vaccine from J07BX03 to 
J07BN04. 
A.6 - Administrative change - Change in ATC 
Code/ATC Vet Code 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
For more information, please refer to the Summary of 
Product Characteristics. 
PSUSA/11035
Periodic Safety Update EU Single assessment - 
14/12/2023 
08/02/2024 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/202305 
SARS-CoV-2, B.1.351 variant, prefusion Spike delta 
the variation to terms of the Marketing Authorisation(s)’ for 
TM protein, recombinant 
PSUSA/11035/202305. 
N/0008 
Minor change in labelling or package leaflet not 
08/12/2023 
08/02/2024 
PL 
connected with the SPC (Art. 61.3 Notification) 
II/0006 
Update of section 4.8 of the SmPC in order to add 
21/09/2023 
08/02/2024 
SmPC and PL 
SmPC new text 
‘Hypersensitivity and anaphylactic reactions’ to the 
list of adverse drug reactions (ADRs) with frequency 
‘Not known’, based on post-marketing data; the 
Package Leaflet is updated accordingly. In addition, 
the MAH took the opportunity to introduce minor 
changes to the PI. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
This variation concerns the update of the Product 
Information to reflect a safety signal of allergic including 
anaphylactic reactions raised by the MAH detected from 
post-marketing data, following a booster dose with 
VidPrevtyn Beta vaccine.  
For more information, please refer to the Summary of 
Product Characteristics. 
Page 2/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0004/G 
This was an application for a group of variations. 
20/07/2023 
n/a 
B.II.d.1.c - Change in the specification parameters 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IB/0002 
B.I.z - Quality change - Active substance - Other 
30/03/2023 
n/a 
variation 
Page 3/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
